“The Global Fetal & Neonatal Care Equipment market is estimated to be worth $8.3bn in 2023” says new Visiongain report

05 October 2018
Pharma

Visiongain has launched a new pharma report: Global Fetal & Neonatal Care Equipment Market Forecast 2018-2028: Fetal, Neonatal, Ultrasound Devices, Fetal MRI Systems, Fetal Monitors, Fetal Pulse Oximeters, Warmer & Incubator, Phototherapy Equipment, Respiratory Devices, Neonatal Monitoring Devices, Hospitals, Clinics, Others

Fetal and neonatal care are emerging as a vital aspect in medical healthcare industry. The fetal and neonatal care comprises measures from early embryonic development through full foetus development and philosophical changes at the time of birth and one month post-delivery as a new born infant. Both fetal and neonatal growth and development are interconnected to the genetic and environmental factors. According to American Academy of Paediatrics, approximately 10% of the infants need birth assistance and ~ 1% need extensive care at the time of birth.

The lead analyst of the report commented "The fetal and neonatal care equipment market is anticipated to witness a strong growth during the forecast period. The key factor attributing to the growth of the market are increasing incidence and prevalence of pre-term birth, still birth, neonatal health complication, and other mother and neonatal pregnancy associated diseases.

The warmer & incubator held the largest share in Neonatal Care Equipment market and is expected to continue leading the market during the forecast period. However, with the increasing awareness for neonates vital analysis, the neonatal monitoring devices is anticipated to witness the second highest growth during the forecast period."

Leading companies featured in the report include Dragerwerk AG & Co. KGaA, Fisher & Paykel, GE Healthcare, Masimo Corporation, Medtronic plc, Natus Medical Inc., Philips Healthcare, Phoenix Medical Systems Pvt. Ltd.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Plasma Therapy Market Report 2021-2031

The market is forecasted for the next ten years based on market growth within each segment of the blood plasma products. The report study aims to explore the market drivers, restraints and also market opportunities facing blood plasma product stakeholders in different geographic areas.

26 November 2020

Read

Visiongain Publishes Precision Cancer Diagnostic Test Market Report 2021-2031

Molecular diagnostics are rapidly transforming drug development and patient selection: trials with biomarkers have higher success rates than those without, and combining patients with a proven biomarker allows efficient trials to be conducted in rare cancers.

26 November 2020

Read

Visiongain Publishes Top 50 Biosimilar Drug Manufacturers 2021

Growing demand for cost-effective drugs; rising prevalence of chronic diseases; mounting investment in drug R&D by biopharmaceutical companies; new product launches and rising acceptance of biosimilars in North America region are some of the major factors that propel the biosimilars market growth.

25 November 2020

Read

Visiongain Publishes Advanced Therapy Medicinal Products (ATMP) Market Report 2021-2031

Currently, the ATMP market is at a nascent stage and is expected to flourish during near future owing to increasing research and development activities and rising use of ATMP therapy products in treatment areas with low or no alternative treatment options support the market growth

24 November 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever